Die Fundamentaldaten des Unternehmens sind relativ sehr gesund. Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Kaufen bewertet. Trotz einer sehr schwachen Entwicklung des Aktienmarktes zeigt das Unternehmen starke Fundamentaldaten. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Aktienbewertung
Zugehörige Informationen
Branchenrang
132 / 207
Gesamtwertung
327 / 4720
Branche
Medizinische Geräte und Verbrauchsmaterialien
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
1
Analysten
Kaufen
Aktuelles Rating
22.000
Kursziel
+171.94%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Unternehmens-Highlights
HöhepunkteRisiko
Sharps Technology, Inc. is a medical device and pharmaceutical packaging company. The Company is engaged in offering patented smart-safety syringe products to the healthcare industry. The Company's smart safety syringe products, such as Securgard, Sologard, and Sharps Provensa, are ultra-low waste syringes that incorporate both passive and active safety and reuse prevention features. It Sharps Securegard and Sologard, and Roncadelle SafeR safety syringe product lines incorporate both active and passive safety features and have been designed to address the three primary administration concerns with syringe delivery systems, including accidental needlestick injuries, wasted medicine/dead space and reuse prevention. It also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. It has a manufacturing facility in Hungary and is pursuing plans to expand its manufacturing capacity in the United States.
Sharps Technology, Inc. is a medical device and pharmaceutical packaging company. The Company is engaged in offering patented smart-safety syringe products to the healthcare industry. The Company's smart safety syringe products, such as Securgard, Sologard, and Sharps Provensa, are ultra-low waste syringes that incorporate both passive and active safety and reuse prevention features. It Sharps Securegard and Sologard, and Roncadelle SafeR safety syringe product lines incorporate both active and passive safety features and have been designed to address the three primary administration concerns with syringe delivery systems, including accidental needlestick injuries, wasted medicine/dead space and reuse prevention. It also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. It has a manufacturing facility in Hungary and is pursuing plans to expand its manufacturing capacity in the United States.